50426-31-8

Basic information

• Product Name: 4-N,4-N-DIMETHYLPYRIDINE-2,4-DIAMINE
• Synonyms: 4-N,4-N-DIMETHYLPYRIDINE-2,4-DIAMINE
• CAS NO: 50426-31-8
• Molecular Weight: 137.184
• Mol File: 50426-31-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-N,4-N-DIMETHYLPYRIDINE-2,4-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N,4-N-DIMETHYLPYRIDINE-2,4-DIAMINE(50426-31-8)
• EPA Substance Registry System: 4-N,4-N-DIMETHYLPYRIDINE-2,4-DIAMINE(50426-31-8)

Safety Data

• Hazardous Substances Data: 50426-31-8(Hazardous Substances Data)

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 124-40-3 dimethyl amine 
• 84539-35-5 (3-bromopyridin-4-yl)-dimethyl-amine 
• 1122-58-3 dmap 
• 114474-08-7 2-amino-5-bromo-4-dimethylaminopyridine 

Relevant articles and documents

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

QUINOLINE DERIVATIVES FOR TREATING CANCER

The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.